類風濕性關節炎市場：現況分析與預測（2024-2032）

Rheumatoid Arthritis Market: Current Analysis and Forecast (2024-2032)

出版日期: 2024年07月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 137 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

類風濕性關節炎（RA）是一種慢性發炎性疾病，主要影響關節，可導致疼痛性腫脹、僵硬、關節畸形和糜爛。這是一種自體免疫疾病，免疫系統錯誤地攻擊身體組織。類風濕性關節炎也會影響其他器官，包括皮膚、眼睛、肺、心臟和血管。這種疾病多發生在30歲至60歲之間，女性比男性更容易受到影響。隨著世界人口老化，RA 的盛行率不斷增加。隨著人們壽命的延長，與年齡相關的疾病的盛行率也會增加，包括 RA 等自體免疫疾病。例如，根據 Census.gov 的資料，65 歲及以上的美國人數量預計將增加 47%，從2022年的 5,800 萬增加到2050年的 8,200 萬人。到2050年，該年齡層人口占總人口的比例預計也將從17%上升至23%。

隨著類風濕關節炎盛行率的上升、認識和診斷的提高是市場成長的主要驅動力，類風濕關節炎市場預計將穩定成長 7.5%左右。根據美國疾病管制與預防中心（CDC）的資料，截至2021年，美國約有 130 萬成年人患有 RA。此外，診斷方法的改進以及生物製劑和標靶合成緩解病情抗風濕藥物（DMARD）的開發也增強了 RA 的管理。這些進步有助於改善患者治療效果並提高診斷率。

依給藥途徑，市場分為口服藥物及腸胃外藥物。其中，口服製劑近年來已風靡市場。口服藥物通常比腸胃外治療更容易施用。患者可以在家中服用口服藥物，無需醫療保健專業人員，增加了便利性和依從性。這對於治療 RA 等慢性疾病尤其重要，長期堅持用藥非常重要。

依藥物類別劃分，市場分為緩解疾病抗風濕藥（DMARD）、非類固醇類抗發炎藥（NSAID）、皮質類固醇、降尿酸藥物等。緩解病情抗風濕藥物（DMARD）對類風濕性關節炎治療市場的收入貢獻顯著，預計在預測期內將大幅成長。這一成長的推動因素包括人們對DMARD 益處的認識不斷提高、類風濕關節炎患病率不斷上升、全球肥胖和超重人數不斷增加，以及DMARD 作為治療類風濕關節炎的一線藥物越來越受歡迎。這些因素共同增加了對 DMARD 的需求並推動市場向前發展。

根據銷售管道，市場分為處方藥和非處方藥。全球市場細分在醫藥市場中，處方藥佔最大佔有率。這項優點歸功於處方藥的好處，例如確保患者服用正確的劑量、最大限度地減少副作用的風險以及防止潛在的藥物濫用。相反，場外交易（OTC）行業預計在預測期內將以最快的速度成長。這種成長是由直接購買非處方藥的便利性以及這些藥物的持續創新和進步所推動的。

為了更了解類風濕性關節炎的市場介紹，市場有北美（美國、加拿大等北美地區）、歐洲（德國、英國、法國、西班牙、義大利等歐洲地區）、亞太地區（中國，該分析基於世界其他地區（日本、印度、亞太其他地區）和世界其他地區的全球存在。在目前2023年的情況下，北美佔據市場主導地位。這一優勢歸因於推動該地區 RA 藥物需求和開發的多種因素，包括高可支配收入、先進的醫療基礎設施和不斷提高的意識。市場上營運的主要公司包括UCB S.A.、F. HOFFMANN-LA ROCHE LTD、Pfizer Inc.、ABBVIE INC.、Novartis AG、Eli Lilly and Company、Teva Pharmaceuticals, Inc.、BRISTOL-MYERS SQUIBB COMPANY、Merck &Co.。

Rheumatoid Arthritis (RA) is a chronic inflammatory disorder primarily affecting joints, leading to painful swelling, stiffness, and potential joint deformity and erosion. It is an autoimmune condition where the immune system mistakenly attacks the body's tissues. RA can also affect other systems, including the skin, eyes, lungs, heart, and blood vessels. This disease predominantly impacts individuals between the ages of 30 and 60, with women being more commonly affected than men. The prevalence of RA is increasing with the aging global population. As people live longer, the incidence of age-related conditions, including autoimmune diseases like RA, rises. For instance, as per the data of Census.gov, The number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% increase. This age group's share of the total population is also expected to rise from 17% to 23% by 2050.

The Rheumatoid Arthritis Market is expected to grow at a steady rate of around 7.5% due to rising prevalence of rheumatoid Arthritis, and increased awareness and diagnosis acting as major drivers for the growth of the market. According to the Centers for Disease Control and Prevention (CDC), approximately 1.3 million adults in the United States were living with RA as of 2021. Further, improved diagnostic methods and the development of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) have enhanced the management of RA. These advancements contribute to better patient outcomes and increased diagnosis rates.

Based on the route of administration, the market is segmented into oral and parenteral. Among these, the oral segment has dominated the market in recent years. Oral medications are generally easier to administer compared to parenteral treatments. Patients can take oral drugs at home without the need for a healthcare professional, which enhances convenience and compliance. This is particularly important for managing a chronic condition like RA, where long-term adherence to treatment is crucial.

Based on the Drug Class, the market is segmented into Disease-modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, and Others. Disease-modifying antirheumatic drugs (DMARDs) are the primary contributors to revenue in the rheumatoid arthritis treatment market, and their growth is expected to be substantial over the forecast period. This growth is driven by increased awareness of the benefits of DMARDs, a rising prevalence of rheumatoid arthritis, a growing global population of obese and overweight individuals, and the widespread adoption of DMARDs as the first-line treatment for rheumatoid arthritis. These factors collectively enhance the demand for DMARDs, propelling the market forward.

Based on the sales channel, the market is segmented into Prescription-based Drugs and Over-the-counter Drugs. The prescription-based drug segment holds the largest share in the global rheumatoid arthritis drugs market. This dominance is attributed to the benefits of prescription medications, such as ensuring patients receive the correct dosage, minimizing the risk of side effects, and preventing potential misuse of drugs. Conversely, the over-the-counter (OTC) drug segment is projected to grow at the fastest rate during the forecast period. This growth is driven by the convenience of purchasing OTC drugs directly and the continuous innovations and advancements in these medications.

For a better understanding of the market adoption of Rheumatoid Arthritis, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2023. This dominance can be attributed to several factors that drive the demand and development of RA therapeutics in the region, such as high disposable income, advanced healthcare infrastructure, and rising awareness. Some of the major players operating in the market include UCB S.A., F. HOFFMANN-LA ROCHE LTD, Pfizer Inc, ABBVIE INC., Novartis AG, Eli Lilly and Company, Teva Pharmaceuticals, Inc., BRISTOL-MYERS SQUIBB COMPANY, Merck & Co., Inc., and JOHNSON & JOHNSON.

1.MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Rheumatoid Arthritis Market
2.2. Research Methodology of the Rheumatoid Arthritis Market
2.3. Respondent Profile

3.EXECUTIVE SUMMARY

3.1. Industry Synopsis
3.2. Segmental Outlook
- 3.2.1. Market Growth Intensity
3.3. Regional Outlook

4.MARKET DYNAMICS

4.1. Drivers
4.2. Opportunity
4.3. Restraints
4.4. Trends
4.5. PESTEL Analysis
4.6. Demand Side Analysis
4.7. Supply Side Analysis
- 4.7.1. Merger & Acquisition
- 4.7.2. Investment Scenario
- 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

5.1. Regional Pricing Analysis
5.2. Price Influencing Factors

6.GLOBAL RHEUMATOID ARTHRITIS MARKET REVENUE (USD BN), 2022-2032F

7.MARKET SEGMENT BY ROUTE OF ADMINISTRATION

7.1. Oral
7.2. Parenteral

8.MARKET SEGMENT BY DRUG CLASS

8.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
8.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
8.3. Corticosteroids
8.4. Uric Acid Drugs
8.5. Others

9.MARKET SEGMENT BY SALES CHANNEL

9.1. Prescription-based Drugs
9.2. Over-the-counter Drugs

10.MARKET INSIGHTS BY REGION

10.1. North America
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe
- 10.2.1. Germany
- 10.2.2. U.K.
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of Asia-Pacific
10.4. Rest of World

11.VALUE CHAIN ANALYSIS

11.1. List of Market Participants

12.COMPETITIVE LANDSCAPE

12.1. Competition Dashboard
12.2. Competitor Market Positioning Analysis
12.3. Porter Five Forces Analysis

13.COMPANY PROFILED

13.1. UCB S.A.
- 13.1.1. Company Overview
- 13.1.2. Key Financials
- 13.1.3. SWOT Analysis
- 13.1.4. Product Portfolio
- 13.1.5. Recent Developments
13.2. F. HOFFMANN-LA ROCHE LTD
13.3. Pfizer Inc
13.4. ABBVIE INC.
13.5. Novartis AG
13.6. Eli Lilly and Company
13.7. Teva Pharmaceuticals, Inc.
13.8. BRISTOL-MYERS SQUIBB COMPANY
13.9. Merck & Co., Inc.
13.10. JOHNSON & JOHNSON